The “treat-to target” concept recommends using biochemical improvement and normalisation (e.g Faecal calprotectin) as an intermediate step towards clinical and endoscopic improvement, with the long-term goal being absence of disability and normalisation of quality of life.

IBD monitoring implies not only monitoring disease activity but also drug exposure (therapeutic drug monitoring where applicable and adherence), monitoring disease-related complications(and those related to medical and surgical treatment) as also quality of life.

In this invigorating conversation with world-renowned expert Dr Tariq Ahmad, I explore the concept, implications, practicalities and indeed the “future” of monitoring in IBD. I hope you enjoy listening, as much as I enjoyed discussing this with Dr Ahmad!